logo-loader

Imugene's Leslie Chong says positive HER-Vaxx data 'validates entire platform'

Published: 23:43 22 Nov 2020 EST

Imugene Limited’s (ASX:IMU) (OTCMKTS:IUGNF) Leslie Chong tells Proactive's Andrew Scott she's delighted with what the interim data has revealed in their ongoing randomised Phase 2 study of HER-Vaxx in gastric cancer. It's shown positive overall survival with a Hazard Ratio of 0.418. The median overall survival for patients receiving HER-Vaxx plus chemotherapy was 14.2 months, compared to 8.8 months in patients treated with chemotherapy alone. Chong says they're now assessing how best to take development of the drug forward.

Imugene with Proactive at ASX Small and Mid Cap Conference

Imugene Ltd (ASX:IMU, OTC:IUGNF) CEO and managing director Leslie Chong chats with Proactive's Jonathan Jackson live from the ASX Small and Mid Cap Conference in March 2024. The biotech stock is a clinical-stage immuno-oncology company that's developing a range of new and novel immunotherapies...

1 day, 14 hours ago